Literature DB >> 8132695

Antitumour activity of coumarin in prostate and mammary cancer models.

E von Angerer1, M Kager, A Maucher.   

Abstract

The antineoplastic and antimetastatic activities of coumarin were evaluated in transplanted prostate tumours of the rat. The growth of Noble Nb-R prostate tumours was strongly inhibited by coumarin (40 mg/kg; administered three times per week), whereas the hormonally more sensitive Dunning R3327-G rat prostate carcinoma did not respond. Coumarin was also shown to possess antimetastatic activity in a Dunning R3327-MatLu tumour model. The number of lung metastases was reduced significantly by 40%-50% following the administration of coumarin (40 mg daily). Preliminary data from experiments with rats bearing DMBA-induced mammary carcinomas showed that these tumours are as sensitive to coumarin as Noble-R-prostate tumours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132695     DOI: 10.1007/bf01377116

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  9 in total

1.  Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation.

Authors:  M Kager; T Spruss; M R Schneider; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Treatment of hormone-refractory stage D carcinoma of prostate with coumarin (1,2-benzopyrone) and cimetidine: a pilot study.

Authors:  M E Marshall; K Butler; D Hermansen
Journal:  Prostate       Date:  1990       Impact factor: 4.104

3.  Treatment of a metastatic prostate derived tumor with surgery and chemotherapy.

Authors:  D Kadmon; W D Heston; W R Fair
Journal:  J Urol       Date:  1982-06       Impact factor: 7.450

4.  Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma.

Authors:  J L Mohler; L G Gomella; E D Crawford; L M Glode; C D Zippe; W R Fair; M E Marshall
Journal:  Prostate       Date:  1992       Impact factor: 4.104

5.  Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma.

Authors:  B Omarbasha; W R Fair; W D Heston
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

6.  Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.

Authors:  A Maucher; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Effects of coumarin (1,2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies.

Authors:  M E Marshall; L K Riley; J Rhoades; T Eichhorn; C D Jennings; M Cibull; J Thompson
Journal:  J Biol Response Mod       Date:  1989-02

8.  Evaluation of the antitumour activity of coumarin in prostate cancer models.

Authors:  A Maucher; M Kager; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  The tumor-inhibiting effect of diethylstilbestrol and its diphosphate on the Nb-H and Nb-R prostatic carcinomas of the rat.

Authors:  M R Schneider; A Humm; A H Graf
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

  9 in total
  3 in total

1.  The anti-neoplastic effects of coumarin: an emerging concept.

Authors:  Shailendra Kapoor
Journal:  Cytotechnology       Date:  2013-01-23       Impact factor: 2.058

2.  New Samarium(III), Gadolinium(III), and Dysprosium(III) Complexes of Coumarin-3-Carboxylic Acid as Antiproliferative Agents.

Authors:  Irena Kostova; Georgi Momekov; Peya Stancheva
Journal:  Met Based Drugs       Date:  2007

3.  Coumarin Derivatives Exert Anti-Lung Cancer Activity by Inhibition of Epithelial-Mesenchymal Transition and Migration in A549 Cells.

Authors:  Rodrigo Santos Aquino de Araújo; Julianderson de Oliveira Dos Santos Carmo; Simone Lara de Omena Silva; Camila Radelley Azevedo Costa da Silva; Tayhana Priscila Medeiros Souza; Natália Barbosa de Mélo; Jean-Jacques Bourguignon; Martine Schmitt; Thiago Mendonça de Aquino; Renato Santos Rodarte; Ricardo Olímpio de Moura; José Maria Barbosa Filho; Emiliano Barreto; Francisco Jaime Bezerra Mendonça-Junior
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.